APLM — Apollomics Income Statement
0.000.00%
- $32.94m
- $30.31m
- $8.50m
Annual income statement for Apollomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 8.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 95.8 | 242 | 177 | 55.5 | 19.7 |
| Operating Profit | -95.8 | -242 | -177 | -55.5 | -11.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -94.8 | -241 | -173 | -53.6 | -10.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -94.8 | -241 | -173 | -53.9 | -10.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -94.8 | -241 | -173 | -53.9 | -10.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -94.8 | -241 | -173 | -53.9 | -10.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -107 | -277 | -193 | -44.5 | -6.79 |